About 1 results

Professors Thomas Dick and Nick Paton at the National University of Singapore have the capacity to develop anti-tuberculosis compounds all the way from target discovery to proof of concept, preclinical and clinical development. They are interested in exploring potential collaborations around chemically validated targets. They also have capability for target identification for compounds with interesting whole cell activity. They are also interested in speaking with researchers with advanced compounds, optimized leads and can support preclinical development if there is mutual interest, including PK, PD, rat tox and formulation. Compounds modulating host response will be considered only if they are at the stage of entering clinical trials.